FINWIRES · TerminalLIVE
FINWIRES

SSY Group's Angina Pectoris Drug Passes Chinese Regulator's Consistency Evaluation

By

SSY Group's (HKG:2005) Diltiazem Hydrochloride Tablets' (30mg) passing of the quality and efficacy consistency evaluation was approved by China's National Medical Products Administration.

The drug is mainly used to treat angina pectoris and mild to moderate essential hypertension, according to a Wednesday Hong Kong bourse filing.

Related Articles